Free tool
FAERS Monitor: Exforge Hct
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022314 or its brand name (Exforge Hct, Amlodipine Besylate, Hydrochlorothiazide, Valsartan). Reports on generic versions are filed under their own applications.
Reports
3,664
Serious
3,408
93% of reports
Hospitalization
993
Death reported
502
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood pressure increased378
- death256
- hypertension231
- wrong technique in product usage process227
- malaise210
- off label use191
- diabetes mellitus188
- dizziness175
- drug ineffective174
- headache173
- blood pressure decreased170
- fatigue146
- feeling abnormal138
- fall134
- cerebrovascular accident126
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 4 |
| 2010 | 48 |
| 2011 | 158 |
| 2012 | 310 |
| 2013 | 216 |
| 2014 | 228 |
| 2015 | 205 |
| 2016 | 262 |
| 2017 | 211 |
| 2018 | 252 |
| 2019 | 252 |
| 2020 | 346 |
| 2021 | 386 |
| 2022 | 335 |
| 2023 | 237 |
| 2024 | 85 |
| 2025 | 69 |
| 2026 | 60 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,495 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood pressure decreasedSignal | 170 | 14.7 | 12.7 | 2,162 |
| blood pressure increasedSignal | 378 | 14.2 | 12.9 | 4,657 |
| diabetes mellitusSignal | 188 | 14.2 | 12.3 | 2,294 |
| wrong technique in product usage processSignal | 227 | 6.4 | 5.7 | 1,046 |
| hypertensionSignal | 231 | 6.3 | 5.5 | 1,026 |
| cerebrovascular accidentSignal | 126 | 4.3 | 3.6 | 315 |
| feeling abnormalSignal | 138 | 3.3 | 2.8 | 222 |
| malaiseSignal | 210 | 2.7 | 2.4 | 237 |
| fallSignal | 134 | 2.3 | 2.0 | 100 |
| dizzinessSignal | 175 | 2.0 | 1.7 | 91 |
| death | 256 | 1.7 | 1.5 | 77 |
| headache | 173 | 1.6 | 1.4 | 38 |
| off label use | 191 | 1.3 | 1.1 | 10 |
| fatigue | 146 | 1.1 | 0.9 | 1 |
| drug ineffective | 174 | 0.8 | 0.7 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.